leisure time -WSS

leisure time

author：Wikipedia 2025-10-04 04:00:56 - browse：7

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： BIO to announce reorganization, senior leaders expected to depart

focus

WSS

To avoid data mishandling cases, universities eye AI and other tools

Primary care doctor shortage won't be solved by free med school tuition

Brain MRIs reveal impact of 'toxic stress' on Black children

Robert F. Kennedy is pitching centrism on health, even on abortion

BIO to announce reorganization, senior leaders expected to depart

The creative science of coining drug names

hotspot

leisure time

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS's proposed rule does nothing to address the climate crisis

After affirmative action ruling, medical educators look to 'holistic review'

To avoid data mishandling cases, universities eye AI and other tools

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Crowdfunding for medical bills sidesteps core problem, author says

BioMarin wins approval for gene therapy to treat hemophilia A

Robert F. Kennedy is pitching centrism on health, even on abortion

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Novel spinal cord stimulator treats paralysis without surgery

leisure time

Medicare threatens to cut off funding for HCA's Mission hospital

AltruBio raises $225 million to develop ulcerative colitis drug

Industry veterans launch new biotech VC with $310M

What should King Charles tell the public about his cancer?

Biden report: The neurospychology of memory and aging

Has Bernie Sanders reached the limit of his pharma bullying effort?

focus

focus

focus

entertainment